View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 6, 2021

Moderna’s Covid-19 vaccine booster doses increase antibody responses

Moderna has reported initial data from its Phase II study, which demonstrated that a single 50µg booster dose of its Covid-19 vaccines, mRNA-1273 or mRNA-1273.351, enhanced neutralising antibody titer responses in previously inoculated people.

The responses were observed against the SARS-CoV-2 virus and two variants of concern, the B.1.351 variant, which was first detected in South Africa, and the P.1 variant found in Brazil.

The mRNA-1273 Covid-19 vaccine is authorised for emergency use for active immunisation to prevent Covid-19 in adults, while mRNA-1273.351 is a booster vaccine candidate based on the B.1.351 variant.

A multivalent booster candidate called mRNA-1273.211, a combination of mRNA-1273 plus mRNA-1273.351, is also being evaluated.

The Phase II study is assessing three ways for increasing neutralising titers in already vaccinated subjects using mRNA-1273.351, mRNA-1273.211 and 50µg mRNA-1273 booster dose.

Data from the trial showed that mRNA-1273.351 booster dose provided increased neutralising antibody titers against the B.1.351 variant than mRNA-1273 booster dose.

Furthermore, safety and tolerability profiles on administering a third booster dose of 50µg mRNA-1273 or mRNA-1273.351 were in line with those noticed following second mRNA-1273 dose in earlier trials.

The vaccine boosters were found to be well-tolerated with mild or moderately severe adverse events.

In addition, the mRNA-1273.351 vaccine had a reduced reactogenicity profile as compared to mRNA-1273 in this Phase II trial.

Moderna CEO Stéphane Bancel said: “The strong and rapid boost in titers to levels above primary vaccination also clearly demonstrates the ability of mRNA-1273 to induce immune memory.

“Our mRNA platform allows for rapid design of vaccine candidates that incorporate key virus mutations, potentially allowing for faster development of future alternative variant-matched vaccines should they be needed.”

Data from the analysis of mRNA-1273.211 is anticipated soon, the company noted.

Parallelly, the National Institutes of Health unit National Institute of Allergy and Infectious Diseases is carrying out a Phase I study of mRNA-1273.351 vaccine.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena